Malignant hyperthermia in North America: Genetic screening of the three hot spots in the type I ryanodine receptor gene

Anesthesiology

Volumn 101, Issue 4, 2004, Pages 824-830

  Sei, Yoshitatsu ^a   Sambuughin, Nyamkhishig N ^b   Davis, Edward J ^a   Sachs, Daniel ^a   Cuenca, Phil B ^a   Brandom, Barbara W ^c   Tautz, Timothy ^d   Rosenberg, Henry ^e   Nelson, Thomas E ^f   Muldoon, Sheila M ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; EXON; GENE; GENE CLUSTER; GENE FREQUENCY; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT HYPERTHERMIA; NORTH AMERICA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RYR1 GENE;

CALCIUM; EXONS; HUMANS; MALIGNANT HYPERTHERMIA; MUTATION; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 4644313202     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200410000-00005     Document Type: Article

References (29)

1. Ellis FR, Heffron JJA: Clinical and biochemical aspects of malignant hyperthermia, Recent Advances in Anesthesia and Analgesia. Edited by Atkinson RS, Adams AP. New York, Churchill-Livingstone, 1985, pp 173-207
2. The European Malignant Hyperpyrexia Group: A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984; 56:1267-9
3. Larach MG for the North American Malignant Hyperthermia Group: Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989; 69:511-5
4. ++ regulating proteins. Curr Mol Med 2002; 2:347-69
5. MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt A, Worton RG: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343:559-61
6. McCarthy TV, Healy JMS, Heffron JJA, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343:562-4
7. Robinson R, Curran JL, Hall WJ, Halsall PJ, Hopkins PM, Markham AF, Stewart AD, West SP, Ellis FR: Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families. J Med Genet 1998; 35:196-201
8. McCarthy TV, Quane KA, Lynch PJ: Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15:410-7
9. Jurkat-Rott K, McCarthy T, Lehmann-Horn F: Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23:4-17
10. Urwyler A, Deufel T, McCarthy T, West S: Guidelines for the molecular genetic detection of malignant hyperthermia susceptibility. Br J Anaesth 2001; 86:283-7
11. Sei Y, Sambuughin N, Muldoon SM: Malignant hyperthermia genetic testing in North America working group meeting. ANESTHESIOLOGY 2004; 100:464-5
12. Monnier N, Romero NB, Lerale J, Landrieu P, Nivoche Y, Fardeau M, Lunardi J: Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Hu Mol Genet 2001; 10:2581-92
13. Lynch PJ, Tong J, Lehane M, Mallet A, Giblin L, Heffron JJA, Vaugjhan P, Zafra G, MacLennan DH, McCarthy TV: A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca release channel function and severe central core disease. Proc Natl Acad Sci U S A 1999; 96:4164-9
14. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Muller CR, Treves S: Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: Association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001; 10:2879-87
15. Davis MR, Haan E, Jungbluth H, Sewry C, North K, Muntoni F, Kuntzer T, Lamont P, Bankier A, Tomlinson P, Sanchez A, Walsh P, Nagarajan L, Oley C, Colley A, Gedeon A, Quinlivan R, Dixon J, James D, Muller CR, Laing NG: Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromusc Disord 2003; 13:151-7
16. Sambuughin N, Sei Y, Gallagher KL, Wyre HW, Madsen D, Nelson T, Fletcher JE, Rosenberg H, Muldoon SM: North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. ANESTHESIOLOGY 2001; 95:594-9
17. Sei Y, Brandom BW, Bina S, Hosoi E, Gallagher KL, Wyre HW, Pudimat PA, Holman SJ, Venzon DJ, Daly JW, Muldoon SM: Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. ANESTHESIOLOGY 2002; 97:1052-8
18. Quane KA, Healy JM, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ording H, Bendixen D, Mortier W, Linz V, Muller CR, McCarthy TV: Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993; 5:51-5
19. Zhang Y, Chen HS, Khanna VK, De Leon S, Phillips MS, Schappert K, Britt BA, Browell AK, MacLennan DH: A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993; 5:46-50
20. Barone V, Massa O, Intravaia E, Bracco A, Di Martino A, Tegazzin V, Cozzolino S, Sorrentino V: Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families. J Med Genet 1999; 36:115-8
21. Brown RL, Pollock AN, Couchman KG, Hodges M, Hutchinson DO, Waaka R, Lynch P, McCarthy TV, Stowell KM: A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Hum Mol Genet 2000; 9:1515-24
22. Sei Y, Gallagher KL, Basile AS: Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes. J Biol Chem 1999; 274:5995-6002
23. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S: B lymphocytes from malignant hyperthermia susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 2001; 276:48077-82
24. Kraev N, Loke JCP, Kraev A, MacLennan DH: Protocol for the sequence analysis of ryanodine receptor subtype 1 gene transcripts from human leukocytes. ANESTHESIOLOGY 2003; 99:289-96
25. Loke JCP, Kraev N, Sharma P, Du G, Patel L, Kraev A, MacLennan DH: Detection of a novel ryanodine receptor subtype 1 mutation (R328W) in a malignant hyperthermia family by sequencing of a leukocyte transcript. ANESTHESIOLOGY 2003; 99:297-302
26. Avila G, O'Connell KMS, Dirksen RT: The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease. J Gen Physiol 2003; 121:277-86
27. Du GG, Sandhu B, Khanna VK, Guo XH, MacLennan DH: Topology of the Ca release channel of skeletal muscle sarcoplasmic reticulum (RyR1). Proc Natl Acad Sci U S A 2002; 99:16725-30
28. Brandt A, Schleithoff L, Jurkat-Rott K, Klingler W, Baur C, Lehmann-Horn F: Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: Novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999; 8:2055-62
29. Galli L, Orrico A, Cozzolino S, Pietrini V, Tegazzin V, Sorrentino V: Mutations in the RYR1 gene in Italian patients at risk for malignant hyperthermia: Evidence for a cluster of novel mutations in the C-terminal region. Cell Calcium 2002; 32:143-51